In-vitro activity of a new oral streptogramin, RPR 106972, alone and in combination with rifampicin or ciprofloxacin against Legionella spp.
The in-vitro activity of RPR 106972, a new oral streptogramin, was compared with that of erythromycin, ciprofloxacin, and rifampicin against 45 Legionella spp. While rifampicin was the most active of all agents tested, RPR 106972 demonstrated activity comparable to that of erythromycin and ciprofloxacin. Usually, indifference was seen when RPR 106972 was tested in combination with rifampicin or ciprofloxacin.
Pendland
S L
SL
College of Pharmacy, University of Illinois, Chicago 60612, USA.
Killian
A D
AD
Woodward
J G
JG
Rodvold
K A
KA
D002939:Ciprofloxacin / Q000494:pharmacology*; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D007875:Legionella / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D012293:Rifampin / Q000494:pharmacology*; D014769:Virginiamycin / Q000494:pharmacology
C099364:RPR 106972; D014769:Virginiamycin; D002939:Ciprofloxacin; D012293:Rifampin